Press Release Archives

Oncotarget News

Oncotarget | Glypican-3 (GPC3) Associated With MCPyV-negative Status and Impaired Outcome in Merkel Cell Carcinoma

August 11, 2022

High prevalence of surface GPC3 makes it a putative drug target.”BUFFALO, NY- August 11, 2022 – A new research paper was published in Oncotarget on August 3,... read more

Oncotarget

Oncotarget | A Novel Mechanism of Regulation of the Oncogenic Transcription Factor GLI3 by Toll-like Receptor Signaling

August 9, 2022

These results increase our understanding of the signaling molecules that can regulate GLI3 in a HH-independent manner.”BUFFALO, NY- August 9, 2022 – A new research paper was published in Oncotarget... read more

Oncotarget

Oncotarget | Chemoradiation Alters PD-L1, CD8+ TILs and Mucin in Rectal Cancer

August 2, 2022

In conclusion, our study provides further data on the immunologic impact of nCRT in rectal cancer.”BUFFALO, NY- August 2, 2022 – A new research paper was published in ... read more

Oncotarget

Oncotarget | CUDC907 Promotes Apoptosis of NF2 Schwannoma Cells

July 26, 2022

CUDC907 has cytotoxic activity in NF2 schwannoma models and primary VS cells and is a candidate for clinical trials.”BUFFALO, NY- July 26, 2022 – A new research paper was... read more

Oncotarget

Oncotarget | Predicting Cancer Immunotherapy Response From Gut Microbiomes Using Machine Learning Models

July 19, 2022

Findings demonstrate how machine learning models can reveal microbiome-immunotherapy interactions that may ultimately improve cancer patient outcomes.”BUFFALO, NY- July 19, 2022 – A new research paper was published in&... read more

Oncotarget

Oncotarget | Continuous Treatment With Abemaciclib Leads to Sustained and Efficient Inhibition of Breast Cancer Cell Proliferation

July 6, 2022

These preclinical results support the unique efficacy and safety profile of abemaciclib observed in clinical trials.”BUFFALO, NY- July 6, 2022 – Researchers from Eli Lilly and Company ... read more

Oncotarget

Oncotarget | New Oncology-Focused Papers Published in Volume 13

June 23, 2022

BUFFALO, NY- June 23, 2022 – At the start of 2022, Oncotarget began publishing research papers in a continuous publishing format in yearly volumes. As of June 23, 2022, Oncotarget has... read more

Figure 3: Similar gene expression patterns between endocrine-resistant breast cancer and triple-negative breast cancer.

Oncotarget

Novel Group of Genes That Cause Endocrine Resistance in Breast Cancer Identified by Dynamic Gene Expression Analysis

June 8, 2022

Our findings identify 34 novel genes for further study as potential therapeutic targets for treatment of endocrine-resistant BC and TNBC.”BUFFALO, NY- June 8, 2022 – A research paper was recently... read more

Figure 1: Development of an NF-κB activity related RNA expression classifier.

Oncotarget

Oncotarget | NF-κB Over-Activation Portends Improved Outcomes in HPV+ HNSCC

May 25, 2022

Since clinicians are exploring therapeutic deintensification for HPV+ HNSCC, identifying patients with good or poor prognosis using the NF-κB Activity Classifier may be useful to guide therapeutic decisions.”BUFFALO,... read more

CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling

Oncotarget

Anti-Cancer Drug Profiling With CancerOmicsNet

May 19, 2022

BUFFALO, NY- May 19, 2022 – A new research paper was published in Volume 13 of Oncotarget, entitled, “CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling.”Researchers from Louisiana State... read more